OR WAIT null SECS
Clarivate Analytics, a global insights and analytics company, announced the launch of its annual “Cortellis Drugs to Watch” report using data and analytics from Cortellis, the company’s suite of life science intelligence solutions. The report highlights seven new drugs forecasted to sell at blockbuster status ($1billion or higher) by 2023.
The drugs include Upadacitinib (AbbVie – US), which treats rheumatoid arthritis; Zolgensma (AveXis – US), which treats spinal muscular atrophy; Roxadustat (AstraZeneca – UK, FibroGen – US, Astellas – Japan), which treats anemia in chronic kidney disease patients on dialysis; Ultomiris (Alexion – US), which treats paroxysmal nocturnal hemoglobinuria; Skyrizi (Boehringer Ingelheim – DE, AbbVie – US), which treats psoriasis; AR-101 (Aimmune Therapeutics – US), which treats peanut allergies; and LentiGlobin (bluebird bio – US), which treats beta-thalassemia in transfusion-dependent patients.
For more information about each drug, how much is forecasted in sales for 2023, and to download the full report, visit here.